New Hypofractionation Radiation Strategies for Glioblastoma
Autor: | J.L. Shah, Melissa Azoulay, Scott G. Soltys, Erqi L. Pollom |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Brain tumor 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Animals Humans Temozolomide Performance status Brain Neoplasms business.industry Chemoradiotherapy medicine.disease Radiation therapy Dose Hypofractionation 030220 oncology & carcinogenesis Quality of Life Radiation Dose Hypofractionation Glioblastoma business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Current Oncology Reports. 19 |
ISSN: | 1534-6269 1523-3790 |
Popis: | Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved. |
Databáze: | OpenAIRE |
Externí odkaz: |